Affordable Access

deepdyve-link
Publisher Website

The EluNIRTM Ridaforolimus Eluting Coronary Stent System.

Authors
  • Savvoulidis, Panagiotis1
  • Perlman, Gidon2, 3
  • Bagur, Rodrigo4, 5
  • 1 a Division of Cardiology , Royal Brompton & Harefield NHS Foundation Trust , London , UK.
  • 2 b Division of Cardiology , Hadassah Hebrew University Medical Center , Jerusalem , Israel. , (Israel)
  • 3 c Medinol Ltd ., Tel Aviv , Israel. , (Israel)
  • 4 d Division of Cardiology , London Health Sciences Centre , London , Canada. , (Canada)
  • 5 e Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences , University of Keele , Stoke-on-Trent , UK.
Type
Published Article
Journal
Expert review of medical devices
Publication Date
Jan 01, 2019
Volume
16
Issue
1
Pages
71–76
Identifiers
DOI: 10.1080/17434440.2018.1549986
PMID: 30452290
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

First-generation drug-eluting stents (DES) were developed and indeed proved their superiority compared to bare-metal stent in minimizing neo-intimal hyperplasia and in-stent restenosis (ISR), overall, reducing target vessel revascularization (TVR). Newer-generation DES are characterized by thinner struts, more biocompatible and either durable, biodegradable or polymer-free surfaces, better device profile and refined drug elution. Area covered: The EluNIRTM (Medinol, Tel Aviv, Israel) Ridaforolimus Eluting Coronary Stent System is a new DES with unique properties. In this review, we highlight the special characteristics of the stent and summarize relevant clinical data. The EluNIRTM was studied in two clinical trials, the NIREUS trial and the larger, pivotal, BIONICS trial. These trials collectively provide data on the safety, performance, and efficacy of the device. Expert commentary: The newly FDA-approved EluNIRTM stent features an elastomeric durable polymer which elutes a novel drug, Ridaforolimus. The stent has thin struts with variable widths and a delivery catheter with a spring tip. These characteristics may explain the good angiographic and clinical results of this stent, which were noninferior to the FDA-approved Medtronic ResoluteTM stent DES.

Report this publication

Statistics

Seen <100 times